DNBseq Platform (next-generation sequencing platform), RT-PCR tests for the detection of the SARS CoV-2 virus and its mutations. Huo-Yan integrated laboratory solution. The NIFTY Test (a non-invasive prenatal test)
BGI Group, formerly Beijing Genomics Institute, is a Chinese genomics company with headquarters in Yantian, Shenzhen. The company was originally formed in 1999 as a genetics research center to participate in the Human Genome Project.[3][4] It also sequences the genomes of other animals, plants and microorganisms.[5]
BGI has transformed from a small research institute, notable for decoding the DNA of pandas and rice plants, into a diversified company active in animal cloning, health testing, and contract research.[6][7][8] BGI's earlier research was continued by the Beijing Institute of Genomics, Chinese Academy of Sciences.[9] BGI Research, the group's nonprofit division, works with the Institute of Genomics and operates the China National GeneBank under a contract with the Chinese government.[10][11] BGI Genomics, a subsidiary, was listed on the Shenzhen Stock Exchange in 2017. MGI was a subsidiary of BGI before it was spun out and listed on the Shanghai Stock Exchange in 2022. [12]
Starting in 2021, details came to light about multiple controversies involving the BGI Group.[13] These controversies include alleged collaboration with the People's Liberation Army (PLA) and use of genetic data from prenatal tests.[14] BGI denied that it shares prenatal genetics data with the PLA.[15]